益佰制药(600594.SH)：2025年度预亏2.85亿元至3.42亿元

Core Viewpoint - The company Yibai Pharmaceutical (600594.SH) is expected to report a significant loss in 2025, with projected net profit attributable to shareholders ranging from -342 million to -285 million yuan [1] Financial Performance - The company anticipates a decline in revenue by 14% due to reduced sales of its main products [1] - Despite an expected decrease in costs and expenses by 18%, the total costs will still exceed revenue, leading to the projected losses [1] - The net profit after deducting non-recurring gains and losses is estimated to be between -336 million and -280 million yuan [1]